Pfizer Inc. today said during its quarterly earnings call that it will file by the end of May for full Food and Drug Administration approval for its COVID-19 vaccine. More than 131 million doses of the Pfizer vaccine have been administered in the U.S. since it was authorized for emergency use in December. In seeking full authorization for adults ages 16 to 85, Pfizer is moving toward directly marketing the shot to consumers. Pfizer also indicated that it will seek FDA’s approval to change the agency’s existing storage guidance, enabling the vaccine to be kept at standard refrigerated temperatures for up to four weeks. The drug maker also expects a FDA decision soon on its application for the vaccine’s emergency use in adolescents aged 12 to 15.

Related News Articles

Headline
Pfizer Inc. today announced that the federal government has agreed to purchase an additional 200 million doses of its COVID-19 vaccine. The deal raises the…
Headline
The Health Resources and Services Administration yesterday awarded rural health clinics about $49,500 each for outreach to increase COVID-19 vaccinations in…
Perspective
The widespread belief that we have completely turned the corner in our fight against COVID-19 does not apply equally to all parts of the country. In many…
Headline
The AHA Board of Trustees yesterday adopted a policy statement that supports hospitals and health systems that adopt mandatory COVID-19 vaccination…
Headline
The AHA, American Medical Association and American Nurses Association today released a public service announcement urging the American public to “ask questions…
Headline
Pfizer today said its COVID-19 vaccine will receive a priority review from the Food and Drug Administration, indicating that Pfizer has completed its…